Get the Stockscreener App
55.60
0.50%
-0.28
After Hours:
55.60
Disc Medicine Inc stock is traded at $55.60, with a volume of 245.69K.
It is down -0.50% in the last 24 hours and down -9.74% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
See More
Previous Close:
$55.88
Open:
$56.2
24h Volume:
245.69K
Relative Volume:
0.68
Market Cap:
$1.91B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-15.15
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-2.44%
1M Performance:
-9.74%
6M Performance:
+29.21%
1Y Performance:
-14.04%
1-Day Range:
$54.77
$56.37
1-Week Range:
$54.24
$59.25
52-Week Range:
$25.60
$77.60
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
55.60 | 1.91B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
WilmerHale Advises Underwriters in Upsized $259.3 Million Follow-on Public Offering of Disc Medicine - WilmerHale
JPMorgan Chase & Co. Purchases 2,257 Shares of Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
How To Trade (IRON) - Stock Traders Daily
Stifel Nicolaus Increases Disc Medicine (NASDAQ:IRON) Price Target to $94.00 - MarketBeat
Stifel raises Disc Medicine stock target to $94, maintains Buy By Investing.com - Investing.com Canada
Stifel raises Disc Medicine stock target to $94, maintains Buy - Investing.com India
Disc Medicine (NASDAQ:IRON) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Disc Medicine’s (IRON) Outperform Rating Reiterated at Wedbush - Defense World
Disc Medicine (NASDAQ:IRON) Sees Unusually-High Trading Volume on Analyst Upgrade - Defense World
FY2026 Earnings Estimate for Disc Medicine Issued By Wedbush - MarketBeat
Disc raises $225.5m as it eyes approval of rare skin disorder drug - Yahoo Finance
Disc Medicine announces pricing of $225.5M upsized public offering - MSN
Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings - Defense World
Disc Medicine Raises $225.5M in Upsized Public Offering to Advance Bitopertin Development - StockTitan
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Disc Medicine (NASDAQ:IRON) Shares Gap DownHere's Why - MarketBeat
Scotiabank Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush - MarketBeat
Cantor Fitzgerald Estimates Disc Medicine FY2025 Earnings - MarketBeat
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria and Shares Plans for NDA Submission - Marketscreener.com
Disc Medicine: Potential Promise Amid Uncertainty (NASDAQ:IRON) - Seeking Alpha
Disc Medicine Announces $200M Public Offering to Advance EPP Treatment Pipeline - StockTitan
Disc Medicine (NASDAQ:IRON) Receives Buy Rating from HC Wainwright - MarketBeat
Wedbush Reaffirms "Outperform" Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc Medicine Announces Successful Type C Meeting with FDA - GlobeNewswire
Disc Medicine Secures FDA Fast-Track Path for Groundbreaking EPP Treatment Bitopertin - StockTitan
Disc Medicine to Host FDA Meeting Update Call on Bitopertin EPP Treatment Progress - StockTitan
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - GlobeNewswire
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Up 6.6% in December - MarketBeat
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Exciting News From a Fast-Growing Biopharma! New Employee Benefits Unveiled! - Zaman
Disc Medicine's SWOT analysis: rare blood disorder stock shows promise By Investing.com - Investing.com Australia
Disc Medicine's SWOT analysis: rare blood disorder stock shows promise - Investing.com India
How the (IRON) price action is used to our Advantage - Stock Traders Daily
Wedbush Reiterates Outperform Rating for Disc Medicine (NASDAQ:IRON) - Defense World
Disc Medicine (NASDAQ:IRON) Earns "Outperform" Rating from Wedbush - MarketBeat
Disc Medicine Highlights 2025 Strategy and Financial Updates - TipRanks
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 - The Manila Times
Disc Medicine Highlights Recent Achievements Across - GlobeNewswire
Disc Medicine Advances EPP Treatment: FDA Fast-Track Talks & $178M Funding Boost Clinical Pipeline - StockTitan
Disc medicine chief legal officer sells $470,657 in stock By Investing.com - Investing.com Australia
Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells $470,625.00 in Stock - MarketBeat
Disc medicine chief legal officer sells $470,657 in stock - Investing.com India
When (IRON) Moves Investors should Listen - Stock Traders Daily
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
John D. Quisel Sells 13,012 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):